Literature DB >> 26337974

Deep brain stimulation induces antiapoptotic and anti-inflammatory effects in epileptic rats.

Beatriz O Amorim1, Luciene Covolan2, Elenn Ferreira3, José Geraldo Brito4, Diego P Nunes5, David G de Morais6, José N Nobrega7, Antonio M Rodrigues8, Antonio Carlos G deAlmeida9, Clement Hamani10,11.   

Abstract

BACKGROUND: Status epilepticus (SE) is a severe condition that may lead to hippocampal cell loss and epileptogenesis. Some of the mechanisms associated with SE-induced cell death are excitotoxicity, neuroinflammation, and apoptosis.
OBJECTIVE: The objective of the present study is to test the hypothesis that DBS has anti-inflammatory and antiapoptotic effects when applied during SE.
METHODS: Rats undergoing pilocarpine-induced SE were treated with anterior thalamic nucleus (AN) deep brain stimulation (DBS). Inflammatory changes and caspase 3 activity were measured within 1 week of treatment.
RESULTS: In pilocarpine-treated rats, DBS countered the significant increase in hippocampal caspase 3 activity and interleukin-6 (IL-6) levels that follows SE but had no effect on tumor necrosis factor α (TNFα).
CONCLUSIONS: DBS has anti-inflammatory and antiapoptotic effects when given to animals undergoing status.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26337974      PMCID: PMC4558969          DOI: 10.1186/s12974-015-0384-7

Source DB:  PubMed          Journal:  J Neuroinflammation        ISSN: 1742-2094            Impact factor:   8.322


Status epilepticus (SE) is a condition associated with continuous seizure activity that often leads to excitotoxicity and cell death [1]. Deep brain stimulation (DBS) of the anterior thalamic nucleus (AN), an approved treatment for medically refractory partial epilepsy [2], has been shown to reduce seizure rate and increase the latency for the development of SE in different rodent models [3-6]. To date, whether stimulation is protective against SE-induced excitotoxicity is largely unknown. In Parkinson’s disease, subthalamic nucleus DBS has been proposed to induce neuroprotective effects by reducing the glutamatergic drive to the substantia nigra [7]. In a parallel scenario, AN stimulation inhibits the spontaneous activity of local neuronal populations and reduces the firing rate of dentate gyrus cells [8]. Following this line of reasoning, we hypothesize that a decreased drive to the hippocampus following AN DBS could have neuroprotective effects. In preclinical models [9] and in the clinic [10, 11], neuromodulation treatments that induce antiepileptic effects, such as vagus nerve stimulation (VNS), have been shown to reduce plasmatic levels of cytokines. In the present study, we test the hypothesis that AN DBS reduces hippocampal apoptosis and neuroinflammation in rats undergoing pilocarpine (Pilo)-induced SE.

Methods

Ethics, consent, and permissions

Experiments were approved by the Animal Care committee of the Universidade Federal de São Paulo (1482/11).

Pilocarpine administration and AN stimulation

Male Wistar rats (~250 g) were anesthetized with ketamine/xylazine (100/7.5 mg/kg i.p.) and had insulated stainless steel electrodes (cathodes; 250-μm diameter; 0.5-mm exposed surface) bilaterally implanted into the AN (anteroposterior −1.5, lateral ± 1.5, depth 5.2) [12]. A screw implanted over the right somatosensory cortex was used as the anode. Control animals had holes drilled into the skull but were not implanted with electrodes. Animals undergoing electroencephalography (EEG) recordings were implanted with bipolar cortical electrodes (Plastics One; 3 mm posterior, 4 mm lateral, and 2 mm ventral to the bregma) [12]. One week later, animals received N-methyl-scopolamine (1 mg/kg s.c. Sigma, St Louis, MO) followed, 30 min later, by pilocarpine (320 mg/kg, i.p., Vegeflora, Brazil). SE was characterized by the presence of uninterrupted behavioral seizures [24]. As pilocarpine-induced seizures often last a few seconds, DBS was commenced 1 minute after SE onset. Stimulation settings were in the range of those used in our previous studies: 130 Hz, 90 μs, and 400 μA (St Jude MTS, Plano, TX) [3]. Ninety minutes after SE, the animals received thionembutal (30 mg/kg) to attenuate behavioral status and reduce mortality rate. As animals began to recover 6 h later, DBS was delivered continuously during the first 6 h of status. EEG was recorded with a BNT-36 system (Lynx, Brazil) using the ENSA software (ENSA, Brazil) for 24 h from the moment Pilo was injected. Signals were amplified, band pass filtered (0.1–30 Hz), and digitized (200 samples/s). Complex Gaussian’s wavelet transform analysis was used to investigate the signals in the frequency domain. Placement of DBS electrodes was confirmed in cresyl-violet-stained sections and was similar to that described in our previous reports [13].

Caspase 3 and cytokine measurements

After removal from the skull, the brains were split in half, and the hippocampus of each hemisphere was dissected. The left hippocampus was used for the study of caspase activity. The right hippocampus was used to measure cytokines. The hippocampus of each animal was incubated with a homogenization buffer and mechanically homogenized, as previously described [14]. Samples were centrifuged for 40 min, and the total protein content in the supernatant determined using the Bio-Rad Protein Assay, according to the manufacturer’s specification (Bio-Rad Labs, Germany). Measurement of caspase 3 activity was obtained using the caspase 3 fluorimetric assay kit (CASP3F, Sigma, USA). Triplicates of each sample (all containing 100 mg of protein) were analyzed. All received the substrate but only one the inhibitor. Activity was measured continuously over 5 h on a FlexStation 3 Spectrofluorimeter (Molecular Probes, USA), using λex = 360 nm and λem = 465 nm. Values obtained from samples containing the inhibitor were subtracted from those recorded from the other samples, and the arithmetic average was calculated. After calibration for AMC, results were expressed as nMol AMC. For cytokine detection, the right hippocampus was homogenized in 0.01 M Tris hydrochloride (pH 7.6) containing 5.8 % sodium chloride, 10 % glycerol, 1 % Nonidet P40 (NP-40), 0.4 % of ethylenediamine tetraacetic acid (EDTA), and protease inhibitors. Samples were sonicated and stored at −80 °C. Subsequently, samples were centrifuged for 5 min. at 10,000 × g at 4 °C, and concentrations determined with a Millipore multiplex Rat Cytokine Kit (RECYTMAG-65K-03) on the Luminex® xMAP® platform (xPonent/Analyst Software version 4.2). Longitudinal controls were used to assess inter-assay variability. Results are expressed in pg/mg.

Statistical analysis

Two-way ANOVA (DBS and Pilo as main factors; Tukey post hoc) was used to compare neurochemical data. Electrophysiological results were analyzed with Wilcoxon signed-rank test. Values in the text represent mean ± SEM.

Results

Apoptosis and neuroinflammatory changes

Hippocampal caspase 3 activity was studied 7 days following SE, a time frame during which apoptosis reaches maximal levels [15, 16]. At this time point, we found significant Pilo (F(1,16) = 17.17; P = 0.0008) and DBS effects (F(1,16) = 10.34; P = 0.005). As can be seen in Fig. 1, caspase 3 activity was increased in pilocarpine-treated rats (n = 5) as compared to saline-injected controls (n = 5; P = 0.009). The administration of DBS significantly reduced such activity (n = 5), bringing it to a level that was similar to that of non-epileptic controls (n = 5; P = 0.02 vs Pilo). In contrast, no significant Pilo (F(1,16) = 0.01; P = 0.95) or DBS effects (F(1,16) = 1.97; P = 0.18) were recorded when caspase 3 activity was measured 24 h following status epilepticus (Additional file 1: Figure S1; n = 5 animals/group).
Fig. 1

DBS, apoptosis, and neuroinflammation. (a) Hippocampal caspase 3 activity was increased in pilocarpine-treated rats undergoing SE (P = 0.009; vs saline controls), an effect that was significantly reversed in the DBS-treated Pilo group (P = 0.02; vs Pilo). Similarly (b), hippocampal levels of the pro-inflammatory IL-6 were significantly increased after SE (P = 0.006; vs saline-injected controls), an effect that was countered by the administration of AN DBS (P = 0.02; vs Pilo). In contrast, SE-induced increases in TNFα (P = 0.0003 vs saline-injected controls) were not influenced by DBS (c). # indicates differences from control, *indicates differences from Pilo

DBS, apoptosis, and neuroinflammation. (a) Hippocampal caspase 3 activity was increased in pilocarpine-treated rats undergoing SE (P = 0.009; vs saline controls), an effect that was significantly reversed in the DBS-treated Pilo group (P = 0.02; vs Pilo). Similarly (b), hippocampal levels of the pro-inflammatory IL-6 were significantly increased after SE (P = 0.006; vs saline-injected controls), an effect that was countered by the administration of AN DBS (P = 0.02; vs Pilo). In contrast, SE-induced increases in TNFα (P = 0.0003 vs saline-injected controls) were not influenced by DBS (c). # indicates differences from control, *indicates differences from Pilo Markers of inflammatory activity were studied 1 day following status, when post-SE changes are at high levels [17, 18]. Hippocampal pro-inflammatory IL-6 was influenced by both Pilo (F(1,14) = 9.85; P = 0.007) and DBS (F(1,14) = 9.23; P = 0.008) with interaction between both factors (F(1,14) = 4.53; P = 0.05). Overall, levels of this interleukin were slightly reduced in AN DBS control animals, a response that was further evidenced after status (P = 0.002 vs Pilo) (Fig. 1). Although TNFα levels were in the lower limit of the detection of the fluorimetric assay, these were found to be influenced by Pilo (F(1,14) = 22.60; P = 0.0003) but not DBS. To investigate whether the protective effects of DBS were due to a decrease in SE severity, EEG recordings were obtained before and during status (n = 5 per group). Though tracings looked similar between groups, spectral analysis revealed that animals receiving DBS had a significant decrease in alpha and beta band peaks (Additional file 2: Figure S2). This suggests that DBS may potentially decrease SE severity.

Discussion

It is well established that seizures and SE can activate intrinsic and extrinsic apoptotic pathways leading to neuronal death. As a common final step, caspase 3 activation invariably leads to an irreversible apoptotic process. In rodents, caspase 3 is active 24–72 h following status but maximally expressed 7 days later [19]. Our results suggest that animals given DBS during status had a significant decrease in hippocampal caspase 3 activity, as measured by a commercial protein assay. While this method was reliable and showed low variability across animals, it did not allow us to determine in which hippocampal subregions apoptosis was occurring. In a preliminary immunohistochemistry experiment (unpublished data), we found that animals undergoing SE with or without DBS had caspase-3-expressing cells in the dentate gyrus, CA1, and CA3 subfields. This technique, however, has only shown sparsely stained cells and a great variability across rats. Whether the effects of DBS are related to a decrease in apoptotic processes or a lower number of hippocampal cells undergoing cell death remains to be elucidated. Another technical aspect that needs to be discussed is the choice of a control group without electrodes implanted. This was based on our previous studies showing that electrode insertion did not influence the latency for developing SE or the frequency of seizures in pilocarpine-treated rats [3, 20]. Placement of electrodes in the brain often causes a mild local inflammatory response that tends to subside over time. Though it is possible that this might have occurred in the AN, samples in our study were collected at a distance from the target (i.e., in the hippocampus and not in the AN). In addition, an inflammatory response should have theoretically increased pro-inflammatory cytokines. In our study, DBS-treated animals had the opposite effect. Most cells in the AN are immunocytochemically positive for glutamate and aspartate [21]. Connections between the AN and hippocampus are both direct (e.g., via subiculum and CA1) and indirect (i.e., via anterior cingulum and entorhinal cortex) [22, 23]. In our previous work, AN DBS was shown to induce a strong depolarization block of local neuronal populations and reduce the firing in hippocampal dentate gyrus cells [24]. Bearing this in mind, it is possible that reduced activity within the AN complex and DG following DBS might have decreased glutamate-induced excitotoxicity, reducing hippocampal caspase activity and inflammatory responses. This, however, still needs to be demonstrated. Another possibility to explain potential neurochemical differences between animals that did or did not receive DBS is that stimulation might have influenced SE severity. Though EEG tracings looked similar between groups, a more detailed spectral analysis revealed that the rats given DBS had a decrease in alpha and beta power. This may represent a milder form of status epilepticus, as the withdrawal of anticonvulsant medications may enhance beta rhythms during continuous seizures [25]. One limitation of the current study is that we cannot infer a direct association between reduced excitotoxicity, anti-inflammatory, and antiapoptotic effects of DBS. Similarly, we are unable to explain why DBS has only influenced certain pro-inflammatory cytokines (i.e., IL-6 but not TNFα).

Conclusion

As excitotoxicity and inflammatory responses are early occurring events following SE, we postulate that the reduced levels of apoptosis observed after DBS may be due, at least in part, to its anti-inflammatory effects. That said, our results do not allow one to establish a causal relationship between a DBS-induced reduction in cytokines and apoptosis, an aspect that needs to be investigated in the future.
  24 in total

1.  Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin.

Authors:  L V Borovikova; S Ivanova; M Zhang; H Yang; G I Botchkina; L R Watkins; H Wang; N Abumrad; J W Eaton; K J Tracey
Journal:  Nature       Date:  2000-05-25       Impact factor: 49.962

2.  Topographic organization of subcortical projections to the anterior thalamic nuclei in the rat.

Authors:  H Shibata
Journal:  J Comp Neurol       Date:  1992-09-01       Impact factor: 3.215

3.  Anterior thalamus deep brain stimulation at high current impairs memory in rats.

Authors:  Clement Hamani; Francisco P Dubiela; Juliana C K Soares; Damian Shin; Simone Bittencourt; Lucience Covolan; Peter L Carlen; Adrian W Laxton; Mojgan Hodaie; Scellig S D Stone; Yoon Ha; William D Hutchison; Andres M Lozano; Luiz E Mello; Maria Gabriela M Oliveira
Journal:  Exp Neurol       Date:  2010-06-14       Impact factor: 5.330

4.  Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy.

Authors:  Robert Fisher; Vicenta Salanova; Thomas Witt; Robert Worth; Thomas Henry; Robert Gross; Kalarickal Oommen; Ivan Osorio; Jules Nazzaro; Douglas Labar; Michael Kaplitt; Michael Sperling; Evan Sandok; John Neal; Adrian Handforth; John Stern; Antonio DeSalles; Steve Chung; Andrew Shetter; Donna Bergen; Roy Bakay; Jaimie Henderson; Jacqueline French; Gordon Baltuch; William Rosenfeld; Andrew Youkilis; William Marks; Paul Garcia; Nicolas Barbaro; Nathan Fountain; Carl Bazil; Robert Goodman; Guy McKhann; K Babu Krishnamurthy; Steven Papavassiliou; Charles Epstein; John Pollard; Lisa Tonder; Joan Grebin; Robert Coffey; Nina Graves
Journal:  Epilepsia       Date:  2010-03-17       Impact factor: 5.864

5.  Microinjection of GABAergic agents into the anterior nucleus of the thalamus modulates pilocarpine-induced seizures and status epilepticus.

Authors:  Simone Bittencourt; Francisco P Dubiela; Claudio Queiroz; Luciene Covolan; Danielle Andrade; Andres Lozano; Luiz E Mello; Clement Hamani
Journal:  Seizure       Date:  2010-03-27       Impact factor: 3.184

6.  Distinct caspase pathways mediate necrosis and apoptosis in subpopulations of hippocampal neurons after status epilepticus.

Authors:  Maria-Leonor Lopez-Meraz; Jerome Niquet; Claude G Wasterlain
Journal:  Epilepsia       Date:  2010-07       Impact factor: 5.864

7.  Vagus nerve stimulation in refractory epilepsy: effects on pro- and anti-inflammatory cytokines in peripheral blood.

Authors:  H J M Majoie; K Rijkers; M W Berfelo; J A R J Hulsman; A Myint; M Schwarz; J S H Vles
Journal:  Neuroimmunomodulation       Date:  2010-07-17       Impact factor: 2.492

8.  Bilateral anterior thalamic nucleus lesions and high-frequency stimulation are protective against pilocarpine-induced seizures and status epilepticus.

Authors:  Clement Hamani; Flavio I S Ewerton; Saulo M Bonilha; Gerson Ballester; Luiz E A M Mello; Andres M Lozano
Journal:  Neurosurgery       Date:  2004-01       Impact factor: 4.654

9.  Expression and activation of caspase 3 following status epilepticus in the rat.

Authors:  Susanna Narkilahti; Terhi J Pirttilä; Katarzyna Lukasiuk; Jarkko Tuunanen; Asla Pitkänen
Journal:  Eur J Neurosci       Date:  2003-09       Impact factor: 3.386

10.  Deep brain stimulation of the anterior nucleus of the thalamus: effects of electrical stimulation on pilocarpine-induced seizures and status epilepticus.

Authors:  Clement Hamani; Mojgan Hodaie; Jason Chiang; Martin del Campo; Danielle M Andrade; David Sherman; Marek Mirski; Luiz E Mello; Andres M Lozano
Journal:  Epilepsy Res       Date:  2007-12-20       Impact factor: 3.045

View more
  8 in total

Review 1.  Neurostimulation as a Method of Treatment and a Preventive Measure in Canine Drug-Resistant Epilepsy: Current State and Future Prospects.

Authors:  Marta Nowakowska; Muammer Üçal; Marios Charalambous; Sofie F M Bhatti; Timothy Denison; Sebastian Meller; Gregory A Worrell; Heidrun Potschka; Holger A Volk
Journal:  Front Vet Sci       Date:  2022-06-16

2.  Chronic Trigeminal Nerve Stimulation Protects Against Seizures, Cognitive Impairments, Hippocampal Apoptosis, and Inflammatory Responses in Epileptic Rats.

Authors:  Qian-Qian Wang; Li-Jun Zhu; Xian-Hong Wang; Jian Zuo; Hui-Yan He; Miao-Miao Tian; Lei Wang; Gui-Ling Liang; Yu Wang
Journal:  J Mol Neurosci       Date:  2016-03-14       Impact factor: 3.444

3.  Unraveling the Role of Astrocytes in Subthalamic Nucleus Deep Brain Stimulation in a Parkinson's Disease Rat Model.

Authors:  Ana Carolina Pinheiro Campos; Daniel Seicho Kikuchi; Amanda Faure Nardini Paschoa; Mayra Akemi Kuroki; Erich Talamoni Fonoff; Clement Hamani; Rosana Lima Pagano; Marina Sorrentino Hernandes
Journal:  Cell Mol Neurobiol       Date:  2020-01-14       Impact factor: 5.046

4.  A 1-year follow-up study on immunological changes following deep brain stimulation in patients with epilepsy.

Authors:  Pabitra Basnyat; Soila Järvenpää; Jani Raitanen; Marko Pesu; Kai Lehtimäki; Jukka Peltola
Journal:  Sci Rep       Date:  2021-07-02       Impact factor: 4.379

5.  Error Analysis and Some Suggestions on Animal Stereotactic Experiment from Inaccuracy of Rhesus Macaques Atlas.

Authors:  Guan-Yu Zhu; Ying-Chuan Chen; Lin Shi; An-Chao Yang; Yin Jiang; Xin Zhang; Jian-Guo Zhang
Journal:  Chin Med J (Engl)       Date:  2016-07-05       Impact factor: 2.628

6.  Deep Brain Stimulation of the Pedunculopontine Tegmental Nucleus Renders Neuroprotection through the Suppression of Hippocampal Apoptosis: An Experimental Animal Study.

Authors:  Chellappan Praveen Rajneesh; Tsung-Hsun Hsieh; Shih-Ching Chen; Chien-Hung Lai; Ling-Yu Yang; Hung-Yen Chin; Chih-Wei Peng
Journal:  Brain Sci       Date:  2020-01-02

7.  Deep brain stimulation of the anterior nuclei of the thalamus relieves basal ganglia dysfunction in monkeys with temporal lobe epilepsy.

Authors:  Tingting Du; Yingchuan Chen; Lin Shi; Defeng Liu; Yuye Liu; Tianshuo Yuan; Xin Zhang; Guanyu Zhu; Jianguo Zhang
Journal:  CNS Neurosci Ther       Date:  2020-10-21       Impact factor: 5.243

8.  Short-Term Amygdala Low-Frequency Stimulation Does not Influence Hippocampal Interneuron Changes Observed in the Pilocarpine Model of Epilepsy.

Authors:  István Mihály; Tímea Molnár; Ádám-József Berki; Réka-Barbara Bod; Károly Orbán-Kis; Zsolt Gáll; Tibor Szilágyi
Journal:  Cells       Date:  2021-03-01       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.